Author:
Abou-Ouf Hatem,Zhao Liena,Bismar Tarek A.
Funder
Prostate Cancer Canada (CA)
Prostate Cancer Foundation (US)
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference121 articles.
1. Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA (2014) Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients’ prognosis. J Hematol Oncol 7:21. doi: 10.1186/1756-8722-7-21
2. Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3(72):72ra17. doi: 10.1126/scitranslmed.3001498
3. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P et al (2008) Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27(3):253–263. doi: 10.1038/sj.onc.1210640
4. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60(16):4629–4637
5. Badawi AF (2000) The role of prostaglandin synthesis in prostate cancer. BJU Int 85(4):451–462
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献